GlassScriptPhysician profile
Aliaksandr Ramaniuk
NPI 1205299070
$40,709.15
in general payments reported to CMS, 2019-2025
25 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.00 · 2022: $1,325 · 2023: $1,112 · 2024: $2,583 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $5,256 · Travel and Lodging: $3,483 · Education: $40.67 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,550.00 |
| Food and Beverage | $5,255.67 |
| Travel and Lodging | $3,483.14 |
| Education | $40.67 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34,869.20 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $3,599.96 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Astrazeneca Pharmaceuticals LP | $987.66 | 2022-2025 | Fasenra, Tezspire, Breztri |
| Amgen INC. | $193.52 | 2022-2025 | Tezspire |
| Genzyme Corporation | $133.48 | 2022-2025 | |
| Fisher & Paykel Healthcare INC | $132.83 | 2024-2025 | Fisher & Paykel Healthcare |
| Verona Pharma, INC. | $122.75 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.33 | 2022-2024 | Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $98.78 | 2023-2025 | Dupixent |
| Insmed, INC. | $56.12 | 2024-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $51.90 | 2024-2025 | Glassia, Hyqvia |
| United Therapeutics Corporation | $50.57 | 2023 | Tyvaso, Orenitram |
| Grifols USA, LLC | $47.49 | 2023-2025 | Prolastin-C Liquid |
| Ekos Corporation | $37.00 | 2019 | |
| Baxter Healthcare | $34.84 | 2023 | Hillrom - Life 2000 Ventilation System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.41 | 2023 | |
| Harmony Biosciences LLC | $21.97 | 2023 | Wakix |
| Jazz Pharmaceuticals INC. | $21.21 | 2023 | |
| Mylan Specialty L.P. | $19.99 | 2024 | Yupelri |
| Astellas Pharma US INC | $18.67 | 2023 | Cresemba |
| Resmed Corp | $17.44 | 2025 | |
| Phadia US INC. | $15.05 | 2024 | Immunocap |
| Axsome Therapeutics, INC. | $14.82 | 2024 | Sunosi |
| Philips North America LLC | $13.28 | 2023 | |
| Genentech USA, INC. | $12.88 | 2023 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliaksandr Ramaniuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.